Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Messenger RNA delivery of a cartilage-anabolic transcription factor as a disease-modifying strategy for osteoarthritis treatment.

Aini H, Itaka K, Fujisawa A, Uchida H, Uchida S, Fukushima S, Kataoka K, Saito T, Chung UI, Ohba S.

Sci Rep. 2016 Jan 5;6:18743. doi: 10.1038/srep18743.

2.

Generation of cleidocranial dysplasia-specific human induced pluripotent stem cells in completely serum-, feeder-, and integration-free culture.

Yamasaki S, Hamada A, Akagi E, Nakatao H, Ohtaka M, Nishimura K, Nakanishi M, Toratani S, Okamoto T.

In Vitro Cell Dev Biol Anim. 2016 Feb;52(2):252-64. doi: 10.1007/s11626-015-9968-x.

3.

A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.

Giotopoulos G, van der Weyden L, Osaki H, Rust AG, Gallipoli P, Meduri E, Horton SJ, Chan WI, Foster D, Prinjha RK, Pimanda JE, Tenen DG, Vassiliou GS, Koschmieder S, Adams DJ, Huntly BJ.

J Exp Med. 2015 Sep 21;212(10):1551-69. doi: 10.1084/jem.20141661.

4.

Osteogenic changes in kidneys of hyperoxaluric rats.

Joshi S, Clapp WL, Wang W, Khan SR.

Biochim Biophys Acta. 2015 Sep;1852(9):2000-12. doi: 10.1016/j.bbadis.2015.06.020.

5.

Runx1 and Runx3 Are Downstream Effectors of Nanog in Promoting Osteogenic Differentiation of the Mouse Mesenchymal Cell Line C3H10T1/2.

Saito T, Ohba S, Yano F, Seto I, Yonehara Y, Takato T, Ogasawara T.

Cell Reprogram. 2015 Jun;17(3):227-34. doi: 10.1089/cell.2014.0059.

6.

BMP-2 Is Involved in Scleral Remodeling in Myopia Development.

Li H, Cui D, Zhao F, Huo L, Hu J, Zeng J.

PLoS One. 2015 May 12;10(5):e0125219. doi: 10.1371/journal.pone.0125219.

7.

Human disease modeling reveals integrated transcriptional and epigenetic mechanisms of NOTCH1 haploinsufficiency.

Theodoris CV, Li M, White MP, Liu L, He D, Pollard KS, Bruneau BG, Srivastava D.

Cell. 2015 Mar 12;160(6):1072-86. doi: 10.1016/j.cell.2015.02.035.

8.

Runx1 Activities in Superficial Zone Chondrocytes, Osteoarthritic Chondrocyte Clones and Response to Mechanical Loading.

LeBlanc KT, Walcott ME, Gaur T, O'Connell SL, Basil K, Tadiri CP, Mason-Savas A, Silva JA, van Wijnen AJ, Stein JL, Stein GS, Ayers DC, Lian JB, Fanning PJ.

J Cell Physiol. 2015 Feb;230(2):440-8. doi: 10.1002/jcp.24727.

9.

Runx1 is critical for PTH-induced onset of mesenchymal progenitor cell chondrogenic differentiation.

Wang J, Wang X, Holz JD, Rutkowski T, Wang Y, Zhu Z, Dong Y.

PLoS One. 2013 Sep 18;8(9):e74255. doi: 10.1371/journal.pone.0074255.

10.

The immediate early gene product EGR1 and polycomb group proteins interact in epigenetic programming during chondrogenesis.

Spaapen F, van den Akker GG, Caron MM, Prickaerts P, Rofel C, Dahlmans VE, Surtel DA, Paulis Y, Schweizer F, Welting TJ, Eijssen LM, Voncken JW.

PLoS One. 2013;8(3):e58083. doi: 10.1371/journal.pone.0058083.

11.

Runx1 dose-dependently regulates endochondral ossification during skeletal development and fracture healing.

Soung do Y, Talebian L, Matheny CJ, Guzzo R, Speck ME, Lieberman JR, Speck NA, Drissi H.

J Bone Miner Res. 2012 Jul;27(7):1585-97. doi: 10.1002/jbmr.1601.

12.

Runx2 protein expression utilizes the Runx2 P1 promoter to establish osteoprogenitor cell number for normal bone formation.

Liu JC, Lengner CJ, Gaur T, Lou Y, Hussain S, Jones MD, Borodic B, Colby JL, Steinman HA, van Wijnen AJ, Stein JL, Jones SN, Stein GS, Lian JB.

J Biol Chem. 2011 Aug 26;286(34):30057-70. doi: 10.1074/jbc.M111.241505.

13.

Metastatic bone disease: role of transcription factors and future targets.

Pratap J, Lian JB, Stein GS.

Bone. 2011 Jan;48(1):30-6. doi: 10.1016/j.bone.2010.05.035. Review.

14.

Dose-dependent effects of Runx2 on bone development.

Zhang S, Xiao Z, Luo J, He N, Mahlios J, Quarles LD.

J Bone Miner Res. 2009 Nov;24(11):1889-904. doi: 10.1359/jbmr.090502.

15.

Adenomatous polyposis coli-mediated control of beta-catenin is essential for both chondrogenic and osteogenic differentiation of skeletal precursors.

Miclea RL, Karperien M, Bosch CA, van der Horst G, van der Valk MA, Kobayashi T, Kronenberg HM, Rawadi G, Akçakaya P, Löwik CW, Fodde R, Wit JM, Robanus-Maandag EC.

BMC Dev Biol. 2009 Apr 8;9:26. doi: 10.1186/1471-213X-9-26.

16.

A Runx2 threshold for the cleidocranial dysplasia phenotype.

Lou Y, Javed A, Hussain S, Colby J, Frederick D, Pratap J, Xie R, Gaur T, van Wijnen AJ, Jones SN, Stein GS, Lian JB, Stein JL.

Hum Mol Genet. 2009 Feb 1;18(3):556-68. doi: 10.1093/hmg/ddn383.

17.

Expression of Runx2 transcription factor in non-skeletal tissues, sperm and brain.

Jeong JH, Jin JS, Kim HN, Kang SM, Liu JC, Lengner CJ, Otto F, Mundlos S, Stein JL, van Wijnen AJ, Lian JB, Stein GS, Choi JY.

J Cell Physiol. 2008 Nov;217(2):511-7. doi: 10.1002/jcp.21524.

18.

Mechanical modulation of osteochondroprogenitor cell fate.

Knothe Tate ML, Falls TD, McBride SH, Atit R, Knothe UR.

Int J Biochem Cell Biol. 2008;40(12):2720-38. doi: 10.1016/j.biocel.2008.05.011. Review.

19.

Concepts in gene therapy for cartilage repair.

Steinert AF, Nöth U, Tuan RS.

Injury. 2008 Apr;39 Suppl 1:S97-113. doi: 10.1016/j.injury.2008.01.034. Review.

20.

Supplemental Content

Support Center